Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer

Official Title

A Phase 2 Multicentre Study of Autologous Tumour Infiltrating Lymphocytes (LN-145) in Patients With Metastatic Non-Small-Cell Lung Cancer

Summary:

This is a prospective, open-label, multi-cohort, non-randomized, multicentre phase 2 study evaluating LN-145 in patients with metastatic NSCLC.

Trial Description

Primary Outcome:

• Objective Response Rate

Secondary Outcome:

• Objective Response Rate
• Complete Response Rate
• Duration of Response
• Disease Control Rate
• Progression-Free Survival
• Overall Survival
• Adverse Events
• Core Biopsies

LN-145 is a ready-to-infuse, autologous TIL therapy that utilizes an autologous TIL manufacturing process, as originally developed by the NCI and further optimized by Iovance for the treatment of patients with metastatic NSCLC. The cell transfer therapy used in this study involves patients receiving an NMA lymphocyte depleting preparative regimen, followed by infusion of autologous TIL, then finally followed by the administration of IL-2.

View this trial on ClinicalTrials.gov